Paladin nice post. Despite the fact that I think management at RVX is very poor I agree there is still great potential opportunity in the science. As we all know the market potential in the CV space alone for Apabetalone is massive. I believe even on a risk adjusted basis the market significantly undervalues the company science and further I think a clearer financial picture will see the share price improve dramatically. I just don't think the market believes anything forward looking from management and has taken a wait and see approach. 

Quite frankly I don't care if BOM2 is on the 2 or the 5 year plan.  The 2 year plan would be nice but my biggest hope here is still that a big pharma is involved and paying. I think big pharma involvement will let the market more fully ascribe value to the science as there will be more confidence that the trial will proceed, well financed and managerially in competent hands.  Further, I think many would say that the chances of clinical success for BOM2 are very much increased with stroke being replaced by HF and even if one ascribes half the potential value of Apabetalone to a big pharma partner there is still a lot of room for significant upside appreciation for the share price. 

On either the 2 or 5 year BOM2 path, with a better share price RVX could do some palatable financing in order to explore some of the other opportunities for Apabetalone as well as in the company's other IP.  Partnerships to this end would likely be more attainable if RVX wasn't perpetually on the verge of bankruptcy.  This would likely be a further positive for share price.

Lastly, the CoVid opportunity seems to be looking very promising and could be a huge opportunity. I think once there is evidence that the clinical trial is actually up and running it will be positive for share price and it could be massively positive if Apabetalone lives up to its CoVid promise.

Hoping for a clearer picture soon!!!!